Navigation Links
Luminex Corporation Awarded $11 Million Contract by Defense Threat Reduction Agency (DTRA)
Date:8/9/2012

AUSTIN, Texas, Aug. 9, 2012 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) announced today it has been awarded a contract worth up to $11.6 million over three and a half years. The contract will fund development of a prototype instrument that is highly portable, field-deployable diagnostic tool capable of rapid detection of biothreat agents and patient response biomarkers indicative of systemic disease. This hand-held system will detect both protein and nucleic acid targets to aid diagnosis of Systemic Inflammatory Response Syndrome (SIRS), a consequence of blood infection in conventional combat, biowarfare and combat operations in developing and resource-limited areas.

(Logo: http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO)

Infection and disease caused by biowarfare agents carry the very real threat of catastrophic illness and death of military and civilian personnel.  The pathophysiology of candidate biowarfare microbes is varied and may involve multiple organ systems, but there are some common features associated with bloodstream infection that permit the development of a sensitive diagnostic test that not only identifies biowarfare pathogens but also can be use outside of an executed bioagent attack.

"Rapid response and informed decisions on therapeutic options are critical in managing biothreat agent exposure," said Amy Altman, Ph.D., vice president Luminex Biodefense. "The flexibility and scalability of our multiplexing technology allow for the measurement of RNA, DNA and proteins with the same system, aiding rapid and accurate diagnosis of these severe conditions.  Development of a field deployable device using our technology has the potential to provide significant advancement in biothreat detection."

"Luminex is highly committed to success in the area of biodefense. We are pleased that DTRA recognizes the potential contribution our technology can make in the detection of biothreat agents," said Patrick J. Balthrop, president and CEO of Luminex.  "We look forward to collaborating on this important initiative by developing innovative solutions for combating biothreat agents and protecting the safety of people everywhere."

The contract awarded to Luminex supports The Chemical and Biological Defense Initiative Fund (CMB-DIAGB2) U.S. Department of Defense's Defense Threat Reduction Agency (DTRA).  Solicitation was issued for full and open competition and 56 proposals were received.  Established in 1998, the Defense Threat Reduction Agency (DTRA) provides the Department of Defense's core intellectual, technical and operational support expertise for countering threats posed by weapons of mass destruction (chemical, biological, radiological, and nuclear) and high-yield explosives.

About Luminex CorporationLuminex is committed to applying its passion for innovation toward advancing healthcare and research worldwide. The Company is transforming global healthcare and life-science research through the development, manufacturing and marketing of proprietary instruments and assays utilizing xMAP® open-architecture, multi-analyte platform and MultiCode® real-time polymerase chain reaction (PCR) and multiplex PCR-based technologies, that deliver cost-effective and rapid results to clinicians and researchers. Luminex's technology is commercially available worldwide and in use in leading clinical laboratories as well as major pharmaceutical, diagnostic, biotechnology and life-science companies. The Company is meeting the needs of customers in markets as diverse as clinical diagnostics, pharmaceutical drug discovery, biomedical research including genomic and proteomic research, personalized medicine, bio-defense research and food safety. For further information on Luminex Corporation and the latest advances in multiplexing using award winning technology, please visit http://www.luminexcorp.com/.Contacts Corporate:

Media: Harriss T. Currie

Mimi TorringtonChief Financial Officer and Vice President, Finance

Director, Marketing CommunicationsLuminex Corporation

Luminex Corporation hcurrie@luminexcorp.com

mtorrington@luminexcorp.com  512.219.8020

512.219.8020 Investors:

Aaron DeLuciaMatthew Scalo

Porter NovelliSr. Director, Investor Relations

Aaron.DeLucia@porternovelli.com Luminex Corporation

512.241.2249mscalo@luminexcorp.com 512.219.8020
'/>"/>

SOURCE Luminex Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Luminex Corporation and University Hospital of Wales Collaborate During Olympic Games
2. Luminex Corporation Reports Second Quarter 2012 Results
3. Luminex Corporation Second Quarter Earnings Release Scheduled for July 30, 2012
4. Luminex Corporation Announces Agreement to Acquire GenturaDx
5. Luminex Corporation Reports First Quarter 2012 Results
6. American Pacific Corporation Commences Debt Refinancing
7. Omeros Corporation Reports Second Quarter 2012 Financial Results
8. Volcano Corporation Presentation At Canaccord Genuity Conference To Be Webcast
9. DURECT Corporation Announces Second Quarter 2012 Financial Results and Update of Programs
10. Volcano Corporation Reports 13 Percent Growth In Second Quarter Revenues; FFR Disposable Revenues Increase 38 Percent
11. HeartWare Completes Acquisition Of World Heart Corporation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) announced ... Act of 1976, as amended ("HSR"), with respect to ... CPXX ) expired effective June 24, 2016, ... previously announced on May 31, 2016, Jazz Pharmaceuticals and ... Jazz Pharmaceuticals has commenced a tender offer for all ...
(Date:6/24/2016)... FRANCISCO, Calif. , June 24, 2016 /PRNewswire/ ... ), a biopharmaceutical company developing novel therapeutics for ... unmet needs, today announced the closing of its ... of common stock, at the public offering price ... in the offering were offered by GBT. GBT ...
(Date:6/24/2016)... , June 24, 2016 Dehaier Medical ... the "Company"), which develops, markets and sells medical devices ... , signed a strategic cooperation agreement with Hongyuan ... "Hongyuan Supply Chain") on June 20, 2016, to develop ... the strategic cooperation agreement, Dehaier will leverage Hongyuan Supply ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... ... June 19, 2016 is World Sickle Cell Observance Day. In an effort ... holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued a pain ... Disease (SCD) is a disorder of the red blood cells, which can cause episodes ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... Conference and Scientific Sessions in Dallas that it will receive two significant new ... the grants came as PHA marked its 25th anniversary by recognizing patients, medical ...
(Date:6/24/2016)... ... 24, 2016 , ... Dr. Amanda Cheng, an orthodontist ... has extensive experience with all areas of orthodontics, including robotic Suresmile technology, ... , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. It can be used ...
(Date:6/24/2016)... ... ... makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business for a Fair Minimum ... by 2020 and then adjusting it yearly to increase at the same rate as the ... wage floor does not erode again, and make future increases more predictable. , The company ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... the Clinical Decision Making in Emergency Medicine conference in Ponte Vedra Beach, FL. ... articles published in Emergency Medicine Practice and Pediatric Emergency Medicine Practice. ...
Breaking Medicine News(10 mins):